Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $2.62 USD
Change Today +0.08 / 3.15%
Volume 826.3K
NBS On Other Exchanges
As of 8:10 PM 04/1/15 All times are local (Market data is delayed by at least 15 minutes).

neostem inc (NBS) Snapshot

Previous Close
Day High
Day Low
52 Week High
04/2/14 - $7.39
52 Week Low
04/1/15 - $2.34
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for NEOSTEM INC (NBS)

Related News

No related news articles were found.

neostem inc (NBS) Related Businessweek News

No Related Businessweek News Found

neostem inc (NBS) Details

NeoStem, Inc., a clinical-stage biopharmaceutical company, develops cell based therapeutics in the United States. It is developing NBS20, a targeted cancer immunotherapy product that is in Phase III clinical trials for the treatment of metastatic melanoma; NBS10, a ischemic repair product that is in Phase II clinical trial to preserve heart muscle function following an acute myocardial infarction; and NBS03D, an immune modulation product that is in Phase II clinical trials for the treatment of type 1 diabetes. The company, through its subsidiary, Progenitor Cell Therapy, offers process development and clinical manufacturing services. It is also involved in oncology, cord blood, and adult stem cell processing and banking activities; and the provision of clinical services. NeoStem, Inc. was founded in 1980 and is headquartered in New York, New York.

182 Employees
Last Reported Date: 03/2/15
Founded in 1980

neostem inc (NBS) Top Compensated Officers

Executive Chairman
Total Annual Compensation: $945.0K
Chief Scientific Officer, President of Progen...
Total Annual Compensation: $494.2K
Chief Medical Officer
Total Annual Compensation: $331.5K
Vice President of Strategic Transactions
Total Annual Compensation: $319.6K
Compensation as of Fiscal Year 2013.

neostem inc (NBS) Key Developments

NeoStem, Inc. Announces PreSERVE AMI Clinical Trial One-Year Follow-Up Results

NeoStem, Inc. announced the presentation of updated efficacy and safety results from the one-year follow-up for its Phase 2 PreSERVE study and additional analyses of certain functional tests at ACC.15, the American College of Cardiology's 64th Annual Scientific Session and Expo, in San Diego, California. The one-year follow-up results are defined as all data accumulated until the last patient enrolled completed 12 month follow-up. Thus, the results actually represent data from patients with a median follow-up of 18 months. The PreSERVE study is NeoStem's clinical trial evaluating NBS10 which is being developed to treat damaged heart muscle following an acute myocardial infarction. One-year follow-up safety data collected thus far supports the trial's 6 month results presented at the American Heart Association's Scientific Sessions in November 2014. The ACC presentation contained updated safety and exploratory efficacy data and additional analyses conducted on left ventricular ejection fraction (LVEF) data. Clinical Endpoint Committee adjudication of major adverse cardiac events (MACE) was performed on the 6 month data reported previously and was not performed for new events (occurring between 6 and 12 months). The next prescribed adjudication of MACE is currently planned at the end of patient follow-up. At 12-month follow-up, no meaningful safety or tolerance differences were observed between treatment and control groups. In this updated analysis, no additional deaths were reported in the treatment or control groups beyond those previously reported in the six month analysis. In addition, in post hoc subset analyses based on the number of cells patients received, serious adverse event (SAE) frequency continues to show numerical improvement at all cell doses when compared to control. Based on the one-year follow-up results, the company and its scientific advisors believe that the study results suggest: intracoronary administration of autologous CD34+ cells appears safe and well-tolerated; a signal for a mortality benefit; and a signal for reduction in the frequency of serious adverse events (SAEs) in higher dose groups.

NeoStem, Inc. Announces Unaudited Earnings Results for the Year Ended December 31, 2014

NeoStem, Inc. announced unaudited earnings results for the year ended December 31, 2014. For the year, the company reported total revenue of $17.9 million compared to $14.7 million in 2013, an increase of 22%. Net loss for 2014 was $55.5 million compared with a $39.5 million loss for 2013. Net loss for 2014 excluding non-cash charges was $45.2 million, compared with $28.7 million for 2013.

Neostem, Inc. Presents at 3rd Annual Regen Med Investor Day, Mar-25-2015 11:20 AM

Neostem, Inc. Presents at 3rd Annual Regen Med Investor Day, Mar-25-2015 11:20 AM. Venue: Metropolitan Club, One East 60th Street, New York, NY 10022, United States. Speakers: David J. Mazzo, Chief Executive Officer and Director.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NBS:US $2.62 USD +0.08

NBS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Cesca Therapeutics Inc $0.92 USD +0.02
Cytori Therapeutics Inc $1.17 USD -0.01
Nuo Therapeutics Inc $0.22 USD -0.0199
StemCells Inc $0.99 USD -0.028
Vericel Corp $3.61 USD -0.09
View Industry Companies

Industry Analysis


Industry Average

Valuation NBS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 5.1x
Price/Book 1.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 3.1x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NEOSTEM INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at